Lanvis

Tioguanine, the active ingredient in Lanvis, is a purine analog presented as an oral formulation for systemic use. It interferes with nucleic acid synthesis and is used in the treatment of specific acute leukemias and other hematologic malignancies, providing cytotoxic activity against rapidly dividing cancer cells.\n\nGNH India supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Tioguanine is a purine analog used in the treatment of hematologic malignancies.\n\n- Acute Myeloid Leukemia (AML): contributes to remission induction and maintenance therapy.\n- Acute Lymphoblastic Leukemia (ALL): used as part of combination chemotherapy regimens.\n- Chronic Myeloid Leukemia (CML): employed in cases resistant to first‑line tyrosine‑kinase inhibitors.

Tioguanine may cause a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Nausea and vomiting: gastrointestinal upset occurring early in therapy.\n- Diarrhea: loose stools that may require supportive care.\n- Myelosuppression: reduced white blood cells, red cells, or platelets.\n- Hepatotoxicity: elevated liver enzymes or mild liver dysfunction.\n- Mucositis: inflammation of the mouth and gastrointestinal lining.\n\nSerious or Rare Side Effects:\n- Severe bone marrow failure: pancytopenia requiring transfusion.\n- Hepatic veno‑occlusive disease: liver vein blockage leading to liver dysfunction.\n- Secondary malignancies: increased risk of therapy‑related cancers.\n- Life‑threatening infections: due to profound immunosuppression.\n- Hypersensitivity reactions: rash, fever, or anaphylaxis.

When prescribing Tioguanine, clinicians should observe several safety considerations to minimize risk.\n\n- Baseline blood counts: obtain complete blood count before initiation and monitor regularly.\n- Liver function monitoring: assess hepatic enzymes and bilirubin at baseline and during treatment.\n- Renal impairment: adjust use in patients with severe kidney dysfunction.\n- Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks.\n- Concomitant myelosuppressive agents: use with caution to prevent excessive bone‑marrow toxicity.\n- Store at ambient temperature: keep in the original container, protect from moisture and light.

Tioguanine interacts with several medicines that can alter its efficacy or toxicity.\n\nMajor Interactions (Avoid):\n- Allopurinol: increases thioguanine nucleotide levels, raising risk of severe myelosuppression.\n- Azathioprine: additive cytotoxicity leading to heightened bone‑marrow suppression.\n- Warfarin: potentiates anticoagulant effect, requiring close INR monitoring.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may increase gastrointestinal irritation and bleeding risk.\n- Sulfonamide antibiotics: can enhance myelosuppressive effects.\n- Fluoroquinolones: may interfere with hepatic metabolism, necessitating periodic blood count checks.